Lumenix Announces New Partnership to Address Future Pandemic Threats in Canada and Around the World

This section is

from GlobeNewswire

Published on May 6, 2024 • 3 minutes reading time

OTTAWA, May 6, 2024 (GLOBE NEWSWIRE) — Lumenix is proud to announce a new partnership with the PRAIRIE Hub for Pandemic Preparedness, which today received nearly $100 million in new federal research grants to support world-leading vaccine and bioproduction research and prepare Canada to prevent future health threats by increasing domestic capacity to produce life-saving vaccines.

The funding was announced by the Hon. Soraya Martinez Ferrada, minister of tourism and minister responsible for the regions of Quebec for the Economic Development Agency of Canada, as part of a series of investments totaling nearly $574 million through the Canadian Biomedical Research Fund and the Biosciences Research Infrastructure Fund the Canada Foundation for Innovation in pandemic preparedness projects five research centers across the country.

Advertising 2

Article content

“The projects we support today will strengthen our ability to deliver medicines, vaccines and therapeutics for the benefit of Canadians,” says Martinez Ferrada. “These collaborations between research centers, post-secondary institutions and research hospitals will promote innovation across the country. Thanks to the work of experienced scientists in institutions at the cutting edge of innovation, Canada will be ready to respond to future health priorities.”

Lumenix is proud to be working on the Viral Vector Vaccine Platforms for Rapid Response to Future Pandemics (3VP) project, managed by the PRAIRIE Hub, a multidisciplinary team that includes the Universities of Manitoba, Alberta and Calgary, as well as the Vaccines and Infectious Diseases sector represents organization at the University of Saskatchewan. The project received $57 million in federal funding to accelerate the development of next-generation vaccines and testing of vaccine efficacy and safety, while supporting the training of high-quality talent in vaccine manufacturing and testing in Canada.

Article content

Advertising 3

Article content

Lumenix is a leading provider of building technologies and artificial intelligence, and its Artificially Intelligent Monitoring System (AIMS) represents the most advanced agile perception system available in the world today. Developed by leading clinicians and engineers at Boston Children’s Hospital, AIMS can anonymously monitor tasks and activities in three dimensions within the clinical and operational environment. By leveraging AIMS platform technology, Lumenix will play a critical role in ensuring process and product consistency while developing optimal standard operating procedures as the hub strengthens Canada’s vaccine bioproduction capacity.

“AIMS is designed to leverage the best of robotics, artificial intelligence and 3D perception systems to address some of the world’s most persistent clinical care and operational challenges,” said Scott Delaney, chairman and CEO of Lumenix. “Our partnership with the PRAIRIE Hub underscores our commitment and vision for the future: to harness the potential of AIMS to help solve global population health challenges and support our public and private sector partners in Canada and around the world in doing so “help to improve standards of health practices, care and research.”

Advertising 4

Article content

The funding announced today represents a significant step toward rebuilding Canada’s biomanufacturing sector, improving Canada’s pandemic preparedness and supporting the innovative and world-leading scientists finding Canadian-made solutions to global challenges.

“The future will bring a collection of alternative vaccines that are best suited to different individuals, and this will require scaling up the production of high quality standardized vaccines in many manufacturing centers worldwide,” says Dr. Maya Shmulevitz, co-director of 3VP, Canada Research Chair in Molecular Virology and Oncotherapy and Professor at the University of Alberta, Department of Medical Microbiology and Immunology. “We are leveraging Lumenix’s cutting-edge AIMS platform technology to quickly standardize vaccine manufacturing, unify best practices and advance vaccine quality and safety worldwide.”

About Lumenix

Lumenix is a leading provider of hardware, software, sensors and artificial intelligence, currently serving and trusted by thousands of customers in the healthcare, commercial, residential, industrial and retail sectors in North America. Lumenix is committed to its vision of providing continuous value and security to its partners and customers through the use of proprietary artificial intelligence, robotics, interconnectivity and clean technologies.

Contact for further information [email protected]

About the PRAIRIE Hub

The PRAIRIE Hub for Pandemic Preparedness is one of five national pandemic preparedness hubs created in 2023 as part of the first phase of the Canadian Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) integrated competition.

The PRAIRIE Hub is led by the University of Alberta and includes the Universities of Manitoba, Calgary, Saskatchewan/VIDO and select other partners from multiple sectors in the Hub region.

For media inquiries please call 613-884-0209